Identification of selective SWI/SNF dependencies in enzalutamide-resistant prostate cancer
Abstract Enzalutamide is a potent second-generation antiandrogen commonly used to treat hormone-sensitive and castration-resistant prostate cancer (CRPC) patients. While initially effective, the disease almost always develops resistance. Given that many enzalutamide-resistant tumors lack specific so...
Saved in:
Main Authors: | , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2025-02-01
|
Series: | Communications Biology |
Online Access: | https://doi.org/10.1038/s42003-024-07413-w |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|